Global
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Spain
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es
Italy
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Italian operations at oncopeptides.it
Change Language
Global
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Spain
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es
Italy
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Italian operations at oncopeptides.it
Change Language
Press release
Oncopeptides have had a number of interactions with the regulatory authorities over the last months, and as a result the company will make preparations to be ready to begin pivotal Phase 3 clinical trials within the next 12 months.